• Anixa delays CAR-T trial in bid to boost efficacy

    3 monthes ago - By Fierce Biotech

    Anixa Biosciences has delayed a planned IND filing by 12 months to buy time to improve its CAR-T candidate. The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.
    Read more ...